A carotid body tumor can occur and are considered a “paraganglioma” since it originates from neurons. They develop in the carotid body which normally helps to regulate oxygen, carbon dioxide ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
(For example, paragangliomas of the adrenal medulla are pheochromocytomas, and paragangliomas of the carotid bifurcation are carotid body tumors.) Lesions may occur in multiples along the extra ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback